Our findings also support extending the use of the α-synuclein PFF animal model for testing therapeutic approaches aimed at protecting mitochondrial homeostasis and function or lowering α-synuclein aggregation to mitigate PFF-induced nigral DA neuron loss, which is the central neuropathology underlying the motor symptoms of PD. This evidence concerns the gene SNCA and Parkinson disease.